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Background: Thrombotic events are a common complication of left ventricular assist device placement and
warrant prophylactic anticoagulation. Heparin is the most common anticoagulant used for prophylaxis of
thrombotic events in left ventricular assist device patients as a transition to oral anticoagulants but carries the risk of
heparin-induced thrombocytopenia. Limited data is available for the treatment of heparin-induced thrombocytopenia
in this patient population. We report an evaluation of 8 left ventricular assist device patients with suspected or
confirmed HIT started on fondaparinux at the time of heparin-induced platelet-factor-4 antibody positivity.
Methods: Adult patients were reported if they were heparin-induced platelet antibody positive, tested via
enzyme-linked immunusorbent assay, post-operative after left-ventricular assist device, and were initiated on
fondaparinux at the time of heparin-induced platelet antibody positivity. Waiver of informed consent was granted
from the institutional review board. Baseline demographics, clinical course of HIT, safety and efficacy variables were
collected.
Results: Eight patients receiving fondaparinux were identified and included in this report. The patient group was
on average 49 years old, weighing 95 kg, with calculated BMI 28.8 and consisted primarily of Caucasian males.
Three patients developed new thromboses after initiation of fondaparinux for heparin-induced thrombocytopenia.
Only one patient had a major bleeding event of an overt bleed after initiation of fondaparinux therapy.
Conclusions: Given the lack of major bleeding in this evaluation, fondaparinux could be a potentially safe
treatment option for left ventricular assist device patients that are heparin-induced platelet antibody positive
pending confirmatory testing results. Given the development of new thromboses in 3 of 8 patients, concern exists
about the efficacy of fondaparinux in this patient population. Significant limitations exist regarding these conclusions in
this evaluation. Controlled, systematic evaluations are necessary to delineate safety and efficacy of fondaparinux for
heparin-induced thrombocytopenia in this population.
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The management of patients with heart failure has pro-
gressed in recent years due to the increased utilization of
ventricular assist devices (VADs), including left ventricular
assist devices (LVADs) [1,2]. According to the Centers for
Disease Control and Prevention, an estimated 5.8 million
people in the United States have heart failure and 550,000
are newly diagnosed with end stage heart failure each year
[1]. Because of this burden, there has been an increased
utilization of LVADs [2]. Data with contemporary LVAD’s
(Heartware and Heartmate II) suggest an increased 1-year
survival compared to historical data of medical therapy and
it is estimated that > 3000 LVADs are implanted worldwide
each year [1-5].
Although LVADs are potentially lifesaving and life
extending, there are serious complications that arise post-
operatively; most prominently bleeding and thrombosis
[6,7]. Bleeding complications often lead to re-operation and
occur more frequently than in other cardiac surgery and
medical patient populations [8-10]. Thrombotic events
in VAD patients occur at a reported incidence ranging
up to 26% and because of this, all LVAD patients will be
transitioned to long-term anticoagulation unless contra-
indicated [11]. Per consensus guidelines, it is recommended
that LVAD patients be bridged with intravenous heparin
to warfarin beginning as early as postoperative day 1
until therapeutic international normalized ratio (INR) is
reached [12].
Given the common use of heparin, LVAD patients have an
increased incidence of heparin-induced thrombocytopenia
(HIT). The incidence approaches ~10%, which is twice
as frequent as other post-surgical populations [13]. Due
to the already high disease-related-rates of thromboses
and significantly higher risk of bleeding complications
at baseline, anticoagulation management for HIT in LVAD
patients presents a clinical challenge.
Alternative anticoagulants that can been considered
for the initial treatment of HIT patients, include selective
factor Xa inhibitors (danaparoid and fondaparinux) and
direct thrombin inhibitors (DTI’s: argatroban, lepirudin,
desirudin, and bivalirudin) [14]. In the United States, the
commonly utilized therapies for HIT include argatroban
and bivalirudin (approved for HIT during percutaneous
coronary intervention). Anecdotally, fondaparinux is
utilized for this indication. One study found success
while utilizing argatroban to manage HIT in VAD patients
without an increased risk of bleeding [15]. Bivalirudin has
been used during cardiac surgery in patients with a history
of HIT, but its use in the treatment of HIT in LVAD
patients has been shown only in case reports [16-18].
Fondaparinux has only one published case specifically
in VAD patients (biventricular VAD only), no published
cases with LVADs, but experience is growing in cardiac
surgery patients [19-21].Fondaparinux has pharmacologic characteristics that
would make it desirable for the use of HIT in this popula-
tion [22]. It is rapidly and completely absorbed after sub-
cutaneous administration requiring no intravenous access.
It also is distributed mainly in the blood which leads to
predictable activity that should not be affected by chan-
ging volume of distribution in hospitalized patients. Fur-
ther, it has peak anti-Xa activity occurring fairly rapidly in
approximately 2–3 hours, requires no biotransformation
for activity or elimination, and has no required monitoring
parameters. Because of this, we investigated our institu-
tional experience utilizing fondaparinux in LVAD patients
with suspected or confirmed HIT.
Methods
This was a retrospective, single-center, tertiary care, aca-
demic medical center evaluation. It was approved by the
Northwestern Medicine Institutional Review Board (IRB)
and due to the retrospective nature of the evaluation,
waiver of informed consent was obtained. Adult patients
(>18 years) who tested positive (optical density [OD > 0.4])
by enzyme-linked immunosorbent assay (ELISA) for
the heparin-induced platelet antibody (HIPA) were identi-
fied and included. A query was done of these patients’
electronic medical records (EMR) from December
2008 to January 2012 for patients who received a LVAD
(Heartware, Heartmate or Heartmate II). These lists
were then cross-referenced to identify those LVAD patients
who were HIPA positive and received fondaparinux during
the evaluation period.
Major bleeding was defined as fatal bleeding, bleeding
in a critical organ (retroperitoneal, intracranial, intraocular,
etc.), deep hematoma, overt bleeding (an acute 2 g/dl
or greater decrease in hemoglobin level), or bleeding
leading to the transfusion of at least 2 consecutive units
of packed red cells (PRBCs) within a 24 hour period.
Thrombosis was detected by clinical suspicion coupled
with standard diagnostic testing. For deep vein throm-
bosis, diagnosis required positive doppler ultrasonography;
for pulmonary embolism, computed tomography was used
to confirm diagnosis; for pump thrombosis, elevations of
lactate dehydrogenase, decrease in haptoglobin, and surgi-
cal attending confirmation were required. Of note, surveil-
lance diagnostic detection was not performed during the
evaluation period. New thrombosis after anticoagulation
was defined as the development of a new thrombosis after
HIT diagnosis until 3-month follow-up. Isolated HIT was
described as HIT with only platelet reduction at time of
diagnosis [23]. Heparin induced thrombocytopenia and
thrombotic syndrome was described as HIT associated
with concomitant thrombosis [23]. Selection of fondapari-
nux for anticoagulation was determined by the treating
providers at the time of treatment and given the retro-
spective nature of this evaluation, reasons for selection
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Heartware patients were started on aspirin 325 mg daily
and Heartmate II patients on aspirin 81 mg daily accord-
ing to hospital protocol. Data is presented in medians and
interquartile ranges (IQR) unless otherwise specified.
Results
Eight patients were identified with a positive HIPA test in
the post-operative setting status post LVAD implantation
that received fondaparinux (Table 1). The patient group
had a median age of 49 years old (7.8 y/o), weighing 95 kg
(21.2 kg), with calculated BMI 28.8 kg/m2 (4.3 kg/m2) and
consisted primarily of Caucasian (87.5%) males (75%).
Only one (12.5%) patient had a history of VTE prior to
admission, no patients had a history of diagnosed bleed-
ing disorders, and two (25%) patients had a history of
chronic kidney disease (CKD; defined as estimated
GFR < 60 mL/min/1.73 m2 for ≥ 3 months). Six (75%)
patients received Heartmate II devices and 2 (25%) received
Heartware LVADs.
The admission median platelet count was 185 k/ul
(70 k/ul) with a median decrease of 48.4% (30.7%) to a
temporal (nearest platelet count within 24 hr to the
HIT + antibody) platelet nadir of 57 k/ul (52 k/ul). The HIT
antibody was drawn 5 days (57.8 days) after admission
to the intensive care unit (ICU) from the operating room.
The 4-T pre-test probability of HIT demonstrated: 4 (50%)
low probability, 3 (37.5%) intermediate probability, and












1 Heartmate II 157 127 0.54 Low
2 Heartmate II 120 80 0.82 Intermed
3 Heartware 203 99 0.44 Intermed
4 Heartware 217 118 0.64 Low
5 Heartmate II 166 102 0.63 Low
6 Heartmate II 218 30 0.45 Intermed
7 Heartmate II 42 16 0.63 Low
8 Heartmate II 526 45 3.15 High
*Temporal Plt Nadir = Plt count nearest (within 24 hr) of HIT antibody + .
**4-T probability: High-probability 6–8 points, intermediate probability 4–5 points, l
***SRA is a send out laboratory assay at our institution with a typical turn-around ti
THITTS = diagnosed thrombosis at the time of HIT antibody + .
TTData unavailable regarding preadmission or outside facility heparin exposure for a
TTTFirst known exposure to heparin was intraoperative.
tPatient developed + HIT antibody on a subsequent admission after initial admission
HIT = heparin-induced thrombocytopenia.
LVAD = left-ventricular-assist device.
Plt = platelet.
OD = optical density.
SRA = serotonin release assay.
HITTS = heparin-induced thrombotic and thrombocytopenic syndrome at time of Hvia ELISA was 1.11 (0.63). Five of the eight (62.5%) patients
received hematology consults to assist in the manage-
ment of HIT. Confirmatory testing with the serotonin
release assay (SRA) was sent on four (50%) patients
(send-out laboratory test at our institution) and one
returned as positive. Of note, the one patient with a
positive SRA also had an ELISA OD of 3.15 and high
probability on 4 T scoring.
At time of diagnosis, 3 (37.5%) patients had heparin-
induced thrombotic-thrombocytopenic syndrome (HITTS)
and 5 (62.5%) with isolated HIT (iHIT). The patients that
presented with HITTS had the following thromboses: 1
patient – DVT alone, 1 patient – DVT, PE, and probable
acute ischemic stroke, and 1 patient – PE alone. Patients
were started on fondaparinux at the time of HIPA positivity
at a median dose of 5 mg (Table 2). The median duration
of fondaparinux treatment was 4.5 days (8 days) with 6
of 8 (75%) patients being transitioned to warfarin before
discharge (2 patients discharged on fondaparinux). All
patients discharged on warfarin were discharged with an
INR within goal range of 2–3.
Three (37.5%) patients developed a new thrombotic
event after the diagnosis of HIT despite the initiation
of fondaparinux transitioned to therapeutic warfarin prior
to discharge (1 patient – PE, 1 patient – LVAD thrombosis,
1 patient – DVT). It was not routine practice during the
evaluation period to perform surveillance diagnostic testing
unless clinical suspicion was raised and thus thromboses
were only diagnosed after clinical concern developed. AllHeme-onc
consult
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Y n/a DVT 17 21
N (−) No 6 10
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Y n/a No 9 8
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Y (+) PE 5 5
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ny patient (eg. cardiac catheterization).
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1 Y 2.5 mg 5 Y 81 mg No No
2 N 2.5 mg 22 N 81 mg LVAD thrombosis No
3 N 5 mg 14 Y 325 mg No No
4 N 5 mg 4 Y 325 mg No No
5 N 5 mg 3 Y 81 mg PE No
6 N 7.5 mg 10 Y 81 mg DVT Overt bleed**
7 N 7.5 mg 3 N 81 mg No Blood transfusion***
8 Y 10 mg 2 Y 81 mg No Blood transfusion***
*All thrombotic events occurred prior to discharge on the admission in which HIT was diagnosed.
**Overt bleeding = ≥ 2 gram g/dL decrease in any 24 hr period.
***Believed to be related to clinical course and unrelated to anticoagulation therapy.
CKD = chronic kidney disease; defined as estimated glomerular filtration rate (GFR) < 60 mL/min/1.73 m2 for > 3 months.
DVT = deep vein thrombosis.
PE = pulmonary embolism.
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receiving fondaparinux presented with iHIT at time of
HIT diagnosis. There were no bleeding events into any
critical organs and no fatal bleeding. One overt bleeding
event was reported, but did not warrant cessation of
anticoagulation or red blood cell transfusion. Two (25%)
patients required red blood cell transfusion after the initi-
ation of fondaparinux though the need for transfusion was
not believed to be related to anticoagulation therapy. In
the two patients that required transfusion, the admission
hemoglobin (Hgb) was 12.4 and 15 mg/dL with a nadir
Hgb 6.7 and 8.6 mg/dL and average Hgb throughout ad-
mission of 9.4 and 10.2 mg/dL, respectively. Each patient
only required one transfusion. No patients died or were
discharged to hospice and all patients were successfully
discharged home or to rehabilitation.
Discussion
In our evaluation we experienced only one major bleeding
episode with the use of fondaparinux for confirmed or
suspected HIT. Given the lack of major bleeding com-
plications, it appears that fondaparinux could be a safe
option for the treatment of HIT in LVAD patients. It is
of special importance to find safe alternative anticoagu-
lants for the treatment of HIT in a patient population
that is already predisposed to bleeding. Post-cardiac sur-
gery patients are at an increased risk of bleeding due to
both surgical and non-surgical causes. Approximately 20%
of post-cardiac surgery patients bleed significantly due
to surgical bleeding [25]. These patients are also at risk
for bleeding because of undergoing cardiopulmonary
bypass (CPB). Cardiopulmonary bypass can increase bleed-
ing due to exposure of procedural high dose anticoagulation
(eg. heparin), extensive surgical trauma, prolonged exposure
of blood to an artificial surface leading to reactant activa-
tion of thrombolysis and fibrinolysis, as well as significantplatelet dysfunction from a CPB-induced loss of receptors
for von Willebrand factor (GP1b) and fibrinogen (GP2b3a)
[26]. Beyond that, patients with continuous flow LVAD
have been shown to develop a relative von Willebrand
factor deficiency which is hypothesized to contribute to the
bleeding incidences in this population [27]. Because we ob-
served minimal bleeding in light of these risks, this agent
may prove to be safe for this patient population.
There is concern for efficacy in this small sample size
due to 3 of the 8 patients developing new thrombotic events
following initiation of fondaparinux after HIT diagnosis.
Data with FDA approved DTI’s, (lepirudin and argatroban)
have demonstrated new thromboses from HIT after
initiation of alternative anticoagulation at lower rates in
other patient populations (6-10% and 13-19% of patients
respectively) [28-34]. Comparison between this historical
data and our evaluation must be made with caution be-
cause the post-cardiac surgery LVAD patient population
carries a significant risk of clotting that others may
not. It has been demonstrated that patients requiring
CPB have a high expression of tissue factor (TF) and
activated factor VII (fVIIa) due to direct contact with the
CPB-circuit [27,35]. This expression leads to the activation
of the contact coagulation pathway as well as activation
of the intrinsic coagulation pathway leading to thrombin
generation. Beyond that, patients that undergo CPB de-
velop systemic inflammation [27]. Through acute-phase
inflammatory reactants such as leukocytes, interleukin
1, tumor necrosis factor, and endotoxin, TF expression
is increased on the endothelium leading to further acti-
vation of the coagulation pathways [27]. Further, LVAD
patients are known to be at a high risk for thrombosis.
Recent evaluation has shown fibrin deposition as a possible
culprit leading to hemolysis, increase in shear stress, and
pump thrombosis [36]. Because of these factors, compari-
sons with historical data are confounded because significant
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LVAD population.
Because fondaparinux has not been systematically studied
in this population for this indication, it is unknown if the
thrombotic observations noted were dose related and if effi-
cacy could be optimized using different dosing strategies. It
is important to note, that based on current treatment rec-
ommendations for acute DVT/PE, only 3 of the 8 patients
evaluated received appropriate weight-based doses [22]. Of
the three patients that developed thrombosis after initiation
of fondaparinux, only 1 of them was on the appropriate
weight-based dose (data not shown). There is recommen-
dation for dose reduction in renal dysfunction, but renal
function data was not collected and thus appropriateness of
dosing cannot be fully evaluated. Because post-operative
LVAD patients often develop varying degrees of renal insuf-
ficiency, there is likelihood that dose modification based on
renal function was present. Without this information, this
is only speculation. Further, during the observation period
and to date there are not recommendations for routine
utilization of anti-Xa serum concentrations to assess
fondaparinux efficacy. If this information were available in
our analysis, firmer conclusions could be made regarding
the efficacy of the current doses in relation to our throm-
botic observations. Also, given the retrospective nature of
this evaluation, it is difficult to determine if thrombotic
variables we observed were related to HIT, its treatment,
or to the clinical course of LVAD therapy.
Confounding our observations further, it appears that
in our evaluation there is potential for a high number
of false positive HIPA tests. Because the 4-T pre-test
probability demonstrated mostly low and intermediate
probability with only one patient with high probability
and only one patient ELISA OD value greater than 1, it is
possible we were treating false-positive HIT antibodies
[24,29]. It has been shown that patients with an ELISA
OD less than 1 only had a 3.4% positive diagnosis for
HIT, an OD 1–2 demonstrated 45.5% positive diagno-
sis, and greater than 2 with 78% positive diagnosis [37].
Of note, the 4-T pre-test probability was calculated
retrospectively and thus this information was not expli-
citly found in the medical record or stated as available for
the treating clinicians. It has been found previously that
there are a large number of false positive HIT antibodies
in post-cardiac surgery patients and that often a low plate-
let count remains so for non-HIT reasons [38-40]. These
patients develop a consumptive thrombocytopenia from
cardiopulmonary bypass required during LVAD implant-
ation which also has been shown to release platelet factor
4 which could lead to false positivity with ELISA testing
[41]. It is also important to point out that only 50% of the
patients in our analysis had confirmatory testing sent
(Table 1) and without confirmatory testing, it is difficult to
know if we are treating true HIT.There are numerous characteristics which would make
fondaparinux an attractive agent in this high-bleeding/
high-thrombotic risk population. First, it has a lower
burden of therapy. One could hypothesize that treatment
with fondaparinux is easier than continuous infusion DTI’s
given it is administered once daily with minimal required
monitoring parameters and does not require intravenous
access. Also, fondaparinux potentially allows for an easier
transition to warfarin than argatroban as it has no signifi-
cant effect on the INR which is desirable as LVAD patients
have indications for warfarin therapy beyond HIT itself
[41]. Because it is distributed in the blood, changes that
occur in LVAD patients’ volume status post-operatively
are not likely to affect the pharmacokinetics and pharma-
codynamics of this medication. Also, it does not need or
undergo hepatic biotransformation which may allow for
utilization in patients that would otherwise be challenging
with argatroban. Though it does require dose modification
for renal dysfunction, more data is emerging on how to
optimize this medication in this patient subset [41].
Lastly, in terms of safety, the major bleeding rates of
fondaparinux when utilized for HIT appear very low
especially in comparison to the bleeding rates with
DTI’s which would be of potential benefit in a patient
group at high risk for bleeding complications such as
LVAD patients, but without head-to-head comparator
trials, this conclusion cannot be confirmed [19,31-33].
All of these attractive characteristics would have to be
balanced with the potential concerns for efficacy seen
in our observations but prospective or large retrospect-
ive comparator trials would be warranted to attempt to
elucidate this information.
Conclusions
Given the low incidence of major bleeding complications
with therapy, fondaparinux may be a useful agent in a
high-bleeding-risk population, such as LVAD patients, for
the treatment of HIT. Based on our observations, concern
for efficacy exists, especially in this highly thrombogenic
patient population. Prospective, multi-center or large
registry comparator evaluations are necessary to further
investigate this question.
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